MAPT and Cognitive impairment: Other disease biomarkers (e.g., cerebrovascular disease and neuroinflammation) should be considered in relation to these modifiable risk factors (e.g. low social contact), elevated amyloid and tau pathology, cognitive impairment, and/or the relationship between pathology and cognitive impairment (i.e., cognitive reserve).10, 11, 12